Ofir Wolach

TL;DR: It is demonstrated that neutrophils from patients with MPNs are primed for NET formation, an effect blunted by pharmacological inhibition of JAK signaling, and suggested that JAK2 inhibition may reduce thrombosis in MPNs through cell-intrinsic effects on neutrophil function.

TL;DR: It is demonstrated that expression of mutant CALR alone is sufficient to engender MPN in mice and recapitulates the disease phenotype of patients with CALR-mutant MPN, and the positive charge of the CALR mutant C-terminus is necessary to transform hematopoietic cells by enabling binding between Mutant CALR and the thrombopoetin receptor MPL.

TL;DR: A systematic review of the literature is presented to compile data to describe better the syndrome of LON, which is generally reported to be in the range of 3%-27%.

TL;DR: Pediatric‐inspired regimens are superior to conventional‐adult chemotherapy in AYA ALL patients and further randomized controlled studies to investigate this approach in adult ALL patients are warranted.

TL;DR: The limited available data suggest that an "acute lymphoblastic leukemia-like" regimen followed by allogeneic stem-cell transplant may be advisable; addition of a tyrosine kinase inhibitor in patients with t(9;22) translocation is recommended.